Odylia Therapeutics Welcomes Elizabeth Attias to Board of Directors
Odylia is looking forward to helping the SATB2 Gene Foundation further SATB2 research through this new partnership....
22 October, 2024
Odylia announced as Amgen Prize finalist for The Odylia Collective
Atlanta, GA, September 10, 2024 — Innovators in Rare Disease Diagnosis and Care Compete for The Amgen Prize and $150,0000 in Prize Funding at the Concordia Annual Summit Odylia announced as top 5 finalist for the Amgen Prize: Innovation for Patients with Rare Disease. Follow the link...
25 September, 2024
Odylia Therapeutics Announces Partnership with Smith Kingsmore Syndrome Foundation
Odylia is looking forward to helping the SATB2 Gene Foundation further SATB2 research through this new partnership....
17 September, 2024
Odylia Therapeutics Receives Translational Research Award from Foundation Fighting Blindness to Accelerate Development of Gene Therapy for RPGRIP1
Atlanta, GA, May 20, 2024 — Odylia Therapeutics, a nonprofit biotechnology company, received a Translation Research Award for $1.5 million from the Foundation Fighting Blindness to accelerate the development of a novel gene therapy (OT-004) to treat vision loss caused by mutations in the RPGRIP1...
20 May, 2024
Medibanx and Odylia Therapeutics Announce Partnership to Advance Patient-Partnered Drug Development Efforts for RPGRIP1-Associated Retinal Dystrophy
Atlanta, GA, October 2, 2023 — Medibanx, a patient-centric platform that powers medical research through the aggregation and analysis of longitudinal real-world patient data, is excited to announce a partnership with Odylia Therapeutics, a nonprofit biotechnology company focused on the development of treatments for people...
03 October, 2023
Odylia CEO & CSO, Ashley Winslow, discusses the Nonprofit Biotech model with Talking Biotech host Kevin Folta
Atlanta, GA -- September 9, 2023 A Non-Profit Biotech Model; Therapies for Rare Diseases - Dr. Ashley Winslow By Colabra • Full Transcript • View the Website This episode has two parts. The first part discusses how Odylia Therapeutics is addressing rare disease, using a novel non-profit model....
02 October, 2023
Odylia contributes to the Affordability Guidance effort spearheaded by the Innovative Genomics Institute
In 2021, IGI’s Public Impact Team launched a year-long Affordability Task Force (ATF) project aimed at solving one of the trickiest challenges for genomic medicines. The report was released in July 2023 and "is the conclusion of a yearlong deliberation by 30 individuals with expertise...
02 October, 2023
Odylia Therapeutics Announces Promotion of Ashley Winslow, Ph.D., to CEO
Odylia is looking forward to helping the SATB2 Gene Foundation further SATB2 research through this new partnership....
11 July, 2023
Odylia Therapeutics Announces Appointment of Khandan Baradaran, Ph.D. to Board of Directors
Odylia is looking forward to helping the SATB2 Gene Foundation further SATB2 research through this new partnership....
04 April, 2023
Odylia Therapeutics Announces Partnership with JEM Therapeutics to Accelerate Drug Development Efforts for TECPR2-Related Disease
Odylia is looking forward to helping the SATB2 Gene Foundation further SATB2 research through this new partnership....
01 March, 2023